Pediatric Focused Safety Review
Precedex™ (dexmedetomidine)
Pediatric Advisory Committee Meeting
April 12, 2016

Amy M. Taylor, MD, MHS
Division of Pediatric and Maternal Health
Office of New Drugs/ ODE IV
Center for Drug Evaluation and Research
Food and Drug Administration
Outline

• Background Information
• Pediatric Studies
• Labeling Changes
• Drug Use Trends
• Safety
• Summary
Background Drug Information
Precedex™ (dexmedetomidine)

- **Drug:** Precedex™ (dexmedetomidine)
- **Formulation:** injection
- **Sponsor:** Hospira
- **Original Market Approval:** December 17, 1999
- **Therapeutic Category:** Selective alpha_2_-adrenergic agonist

- Information related to studies in pediatric patients added to the labeling in June 2013 initiated this safety review.
Background Drug Information, continued

Precedex™ (dexmedetomidine)

Adult Indications

- Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting not to exceed 24 hours.

- Sedation of non-intubated patients prior to and/or during surgical and other procedures.

There are no pediatric indications.
None

**Warnings and Precautions** (section 5)

- **Drug Administration**
  - only administered in intensive care or operating room setting.
- **Hypotension, Bradycardia and Sinus Arrest**
- **Transient Hypertension**
- **Arousability**
  - some patients receiving Precedex have been observed to be arousable and alert when stimulated.
- **Withdrawal**
  - adverse events associated with withdrawal of Precedex (e.g. nausea, vomiting and agitation)
Outline

- Background Information
- **Pediatric Studies**
- Labeling Changes
- Drug Use Trends
- Safety
- Summary
Pediatric Studies
Precedex™ (dexmedetomidine)

One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of Precedex for this patient population.*

These are the studies that initiated today’s safety review.

*June 2013 labeling update
Outline

• Background Information
• Pediatric Studies
• Labeling Changes
• Drug Use Trends
• Safety
• Summary
Pediatric Labeling Changes
Precedex™ (dexmedetomidine)

8.4 Pediatric Use
• Description of the studies conducted and a statement that the use of Precedex for procedural sedation in pediatric patients has not been evaluated*

*June 2013 labeling update
Outline

• Background Information
• Pediatric Studies
• Labeling Changes
• Drug Use Trends
• Safety
• Summary
Drug Utilization Data: dexmedetomidine
Nationally Estimated Number of Patients with Inpatient and Outpatient Billing for Dexmedetomidine HCl Injection from U.S. Non-Federal Hospitals, from June 2014 through May 2015

<table>
<thead>
<tr>
<th>Age Group</th>
<th>June 2014–May 2015</th>
<th>Share %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients N</td>
<td></td>
</tr>
<tr>
<td>Total Patients</td>
<td>571,019</td>
<td>100%</td>
</tr>
<tr>
<td>0-16 years</td>
<td>104,353</td>
<td>18.3%</td>
</tr>
<tr>
<td>0-1 years</td>
<td>23,082</td>
<td>22.1%</td>
</tr>
<tr>
<td>2-11 years</td>
<td>65,852</td>
<td>63.1%</td>
</tr>
<tr>
<td>12-16 years</td>
<td>15,419</td>
<td>14.8%</td>
</tr>
<tr>
<td>17+ years</td>
<td>466,666</td>
<td>81.7%</td>
</tr>
</tbody>
</table>

Pediatric Drug Utilization: dexmedetomidine

Nationally Estimated Number of Pediatric Patients* (0-16 years) with Inpatient and Outpatient Billing for Dexmedetomidine HCl Injection from U.S. Non-Federal Hospitals, Stratified by Patient Age**, from June 2010 through May 2015, yearly

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1 years</td>
<td>56,804</td>
<td>55,939</td>
<td>82,689</td>
<td>104,266</td>
<td>104,353</td>
</tr>
<tr>
<td>2-11 years</td>
<td>20,000</td>
<td>40,000</td>
<td>60,000</td>
<td>80,000</td>
<td>100,000</td>
</tr>
<tr>
<td>12-16 years</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
</tbody>
</table>

*Patient age groups are inclusive of all patients up to the day before their next birthday

**Patient age subtotals may not sum exactly due to patients aging during the study, and may be counted more than once in the individual age categories. Therefore, summing across patient age bands will result in overestimates of patient counts.

Outline

- Background Information
- Pediatric Studies
- Labeling Changes
- Drug Use Trends
- Safety
- Summary
Number* of Adult and Pediatric FDA Adverse Event Reporting System (FAERS) Cases with Precedex™ (December 17, 1999 to May 31, 2015)

<table>
<thead>
<tr>
<th></th>
<th>All reports (US)</th>
<th>Serious† (US)</th>
<th>Deaths (US)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (≥ 17 yrs.)</td>
<td>362 (123)</td>
<td>321 (107)</td>
<td>51 (16)</td>
</tr>
<tr>
<td>Pediatrics (0- &lt;17 yrs.)</td>
<td>69 (29)</td>
<td>56 (25)</td>
<td>2 (0)</td>
</tr>
</tbody>
</table>

* May include duplicates and transplacental exposures; cases have not been assessed for causality
†Serious adverse drug experiences per regulatory definition (CFR 314.80) include outcomes of death, life threatening, hospitalization (initial or prolonged), disability, congenital anomaly, and other serious important medical events.
Selection of Pediatric FAERS Cases

Pediatric reports with a serious outcome (n=56)
  Pediatric reports with the outcome of death (n=2)

Excluded Reports* (n=19)
  (Including 0 deaths)
  • Duplicates (n=19)

Pediatric Case Series (n=37)
  (Including 2 deaths)

* These 19 reports were reviewed and excluded from the case series for the stated reasons.
# Characteristics of Pediatric Case Series

**Precedex™ (dexmedetomidine)**

## Characteristics of Pediatric Case Series with Dexmedetomidine (N=37)

<table>
<thead>
<tr>
<th>Age</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - &lt;1 month</td>
<td>4</td>
</tr>
<tr>
<td>1 month - &lt;2 years</td>
<td>13</td>
</tr>
<tr>
<td>2 - &lt;6 years</td>
<td>5</td>
</tr>
<tr>
<td>6 - &lt;12 years</td>
<td>10</td>
</tr>
<tr>
<td>12 - &lt;17 years</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indication</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation (n=34)</td>
<td></td>
</tr>
<tr>
<td>Ventilated</td>
<td>18</td>
</tr>
<tr>
<td>Non-ventilated</td>
<td>8</td>
</tr>
<tr>
<td>Procedural</td>
<td>6</td>
</tr>
<tr>
<td>Post-surgical sedation</td>
<td>2</td>
</tr>
<tr>
<td>Unknown ventilation status</td>
<td>8</td>
</tr>
<tr>
<td>Other (n=3)</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>1</td>
</tr>
<tr>
<td>Seizure control</td>
<td>1</td>
</tr>
<tr>
<td>Unintended administration</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Infusion</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term (≤24 hrs)</td>
<td>13</td>
</tr>
<tr>
<td>Long-term (&gt;24 hrs)</td>
<td>14</td>
</tr>
<tr>
<td>Unknown</td>
<td>8</td>
</tr>
</tbody>
</table>
Fatal cases Precedex™ (n=2)

- A 10 year old female with history of Rett’s syndrome and scoliosis surgery received a dexmedetomidine infusion on Day 1 (unknown dose, unknown indication). Within 20-30 minutes after the start of the infusion, she experienced severe hypotension and bradycardia. Dexmedetomidine was discontinued. She was given cardiac resuscitation, but died on Day 4.

- This death was possibly related to dexmedetomidine; however, her history of Rett’s syndrome, which can include cardiac arrhythmias, and unknown concomitant medications were confounders.
Fatal cases Precedex™ continued (n=2)

- A 15 day-old male was born at 24 weeks gestational age with low birth weight, hyaline membrane disease, bronchopulmonary hemorrhage, patent ductus arteriosus, intracranial hypertension, intraventricular hemorrhage, septic shock (*Staph*), renal failure, seizures, and cholestasis began receiving dexmedetomidine for sedation one day prior to death. The next day cardiac ultrasound showed reduced cardiac flow, bradycardia, left ventricular hypertrophy (interventricular septum = 3 mm), diastolic dysfunction, and evidence of hypertrophic myocarditis. He then died. Autopsy findings reported the following drug levels [dexmedetomidine=6.2 ng/mL (reported as “3x above” expected), sufentanil=8.7 ng/mL, and ‘levopromazine’=491 ng/mL] and findings consistent with his underlying prematurity and known pathologies.

- The dexmedetomidine level was elevated; however, the patient’s significant morbidity and exposure to other medications were confounders.
Serious Non-Fatal Adverse Events†
Precedex™ (dexmedetomidine) (n=35)

Cardiovascular (n=16)
- **Syncope** (n=3)
- **Cardiac failure** (n=2)
- **Torsade de pointes** (n=1)
- Cardiac arrest (n=4)
- Bradycardia (n=1)
- QT prolongation* (n=2)
- Tachycardia (n=2)
- Supraventricular tachycardia (n=1)

*QT prolongation is considered labeled for the purposes of this review since it is included in the dexmedetomidine HQ Specialty Pharma labeling.

†Unlabeled events are underlined.
Serious Non-Fatal Adverse Events†
Precedex™ (dexmedetomidine) (n=35)

Neuropsychiatric (n=10)
• Encephalopathy (n=2)
• Cerebral infarction (n=1)
• Convulsion (n=4)
• Communication/speech disorder (n=2)
• Psychosis (n=1)

†Unlabeled events are underlined.
Serious Non-Fatal Adverse Events†
Precedex™ (dexmedetomidine) (n=35)

Medication Errors and related clinical event (n=3)
  – Errors include overdose and unintentional administration
  • Hypoglycemia (n=1)
  • Sedation (n=1)
  • Bradycardia (n=1)

Hypersensitivity (n=2)
  • Drug reaction with eosinophilia and systemic symptoms (n=1)
  • Anaphylactic reaction (n=1)

†Unlabeled events are underlined.
Serious Non-Fatal Adverse Events†
Precedex™ (dexmedetomidine) (n=35)

Other (n=4)
- Hepatitis fulminant (n=1)
- Hypothermia (n=1)
- Adrenal insufficiency (n=1)
- Upper airway obstruction (n=1)

†Unlabeled events are underlined.
Summary of Safety Reviews
Precedex™ (dexmedetomidine)

• This concludes the pediatric focused safety review of FAERS reports.

• No new safety signals were identified.

• FDA recommends continuing routine, ongoing post-marketing safety monitoring.

• Does the committee concur?
ACKNOWLEDGEMENTS

DAAAP
Allison Meyer
Leah Crisafi, MD
Rigoberto Roca, MD

OSE
Martin Pollock, PharmD
Jennie Wong, PharmD
Sara Camilli, PharmD, BCPS
Rajdeep Gill, PharmD
S. Christopher Jones, PharmD, MS, MPH
LCDR Grace Chai, PharmD

DPMH
Ethan D. Hausman, MD
Denise Pica-Branco, PhD
Hari Cheryl Sachs, MD
John Alexander, MD, MPH
Lynne Yao, MD

OPT
Judith Cope, MD, MPH
Robert “Skip” Nelson, MD, PhD
Amy Odegaard, MPH
Pam Weinel, MS, MBA, RN
LCDR Kenneth Quinto, MD, MPH